U.S., Jan. 29 -- ClinicalTrials.gov registry received information related to the study (NCT06797544) titled 'Intralesional Injection of Levofloxacin for the Management of Cutaneous Leishmaniasis' on Jan. 17.
Brief Summary: Aim of the study to evaluate the effectiveness of intralesional levofloxacin 0.5% solution as a local injection in treating cutaneous leishmaniasis.
In an open-label single-arm clinical trial, all patients were given intralesional levofloxacin injections; the patients had cutaneous leishmaniasis lesions. Each lesion was considered a case in the final analysis. Each lesion will be followed up for 90 days (censor endpoint) or until the lesions are cured.
Intralesional levofloxacin (5 mg/ml, 100 ml, Tavanic(R), Sanofi, Fr...